Biocept Inc (NASDAQ: BIOC) announced Monday the availability of 10,000 nasopharyngeal specimen collection kits used in the RT-PCR testing for the SAR-CoV-2 virus that causes the COVID-19 disease.
Collected specimens will be shipped overnight to Biocept's high-complexity, CLIA-certified, CAP-accredited and BSL-2 safety level laboratory in San Diego with results returned to ordering physicians in an estimated 24 to 48 hours, the company said.
"As previously reported, securing specimen collection kits to conduct RT-PCR COVID-19 testing has been challenging both for Biocept and other providers,” said CEO Michael Nall in a statement.
“We have solved our initial supply chain challenge by obtaining the swabs, reagents and other components of these kits, assembling them, and making them available for physician ordering.”
Nall said the company expects the Biocept-developed RT-PCR COVID-19 kits to be available in the third quarter of 2020.
"We are pleased to be offering this testing during the continuing pandemic, with RT-PCR testing providing the most accurate results for detecting active COVID-19 virus," he added.
Nall said Biocept expanded its relationship with Thermo Fisher Scientific to run the tests on Thermo’s molecular diagnostic platform that has won emergency-use authorization from the US Food and Drug Administration.
Contact the author: firstname.lastname@example.org
Follow him on Twitter @PatrickMGraham